Genomas Clinical Study Finds Increased Prevalence Of Drug Metabolism Deficiencies In Patients With Serious Psychotropic Side Effects

Results from a clinical study published in the current issue of the Future Medicine Group (London) journal Personalized Medicine (Vol. 5, No. 6, pp. 579-587, 2008) are helping to point the way toward the application of DNA-guided medicine to predict psychotropic side effects. The study was conducted at The Institute of Living of Hartford Hospital in collaboration with Genomas.

More: continued here

Filed under: Clinical Trials on December 11th, 2008